Congenital Heart Disease Study

Dr. Thomas Jones, MD, Director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital discusses congenital heart disease and the importance for this patient population to “stay in care” during the COVID-19 pandemic.  He also discusses late-breaking data that was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 on the Medtronic Melody™ transcatheter pulmonary valve 10-year study results.

Thomas K. Jones, MD, is director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital and professor in the Department of Pediatrics at the University of Washington School of Medicine. He earned his MD at Jefferson Medical College in Philadelphia. He completed his pediatrics residency at the University of Washington and his pediatric cardiology fellowship at the University of Colorado and the Denver Children’s Hospital. He is a fellow of the American Academy of Pediatrics, the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions. Jones’ work has focused on congenital interventional cardiac catheterization, and he has been co-investigator on virtually every multicenter clinical trial in the United States evaluating devices and procedures developed for this patient population. He has served on numerous national committees and task forces promoting guidelines and practice standards for patients with congenital heart disease. Jones collaborates with emerging technology companies developing and testing new products designed to treat these conditions.